Nov 5 (Reuters) – T-Therapeutics: * T-THERAPEUTICS ANNOUNCES OVERSUBSCRIBED $133 MILLION SERIES B FINANCING TO ACHIEVE CLINICAL PROOF-OF-CONCEPT FOR FIRST-IN-CLASS TCR BISPECIFIC THERAPIES IN CANCER
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
OSLO, Nov 5 (Reuters) - Norway's central bank kept its policy interest rate on hold…
VIDEO SHOWS: STILLS OF BAYERN MUNICH STRIKER HARRY KANE WITH BALLON D'OR TROPHY / ARCHIVE…
By Mirac Dereli Nov 5 (Reuters) - Turkish Airlines Chairman Murat Seker said late on…
By Sam Nussey TOKYO, Nov 5 (Reuters) - Sony on Thursday reported a 45% rise…
By Anton Bridge and Kane Wu Nov 5 (Reuters) - China's state planner has told…
MUMBAI, Nov 5 (Reuters) - India's Kotak Mahindra Prime accepted bids for 5.5 billion rupees…